Dr. Anton Franken is a Consulting Physician Internal Medicine and Clinical Expert in Drug (Biosimilar) Development, especially in Phase I – II Clinical Trials.
Dr. Franken is an expert in Biosimilars development and a former member of the Dutch Medicines Evaluation Board (CBG-MEB ) and a former Board member of Biosimilars Nederland (IBN).
Dr. Michał Nowicki is a medical professional with degrees in Medicine and Pharmacy from the Poznan University of Medical Sciences. As a Medical Officer and Consultant at Biokinetica Early Phase Institute in Berlin, he oversees active clinical trials, prepares reports, engages with sponsors, and qualifies volunteers for First-in-Human trials. His expertise also includes Biosimilars and their development.
Previously, Dr. Nowicki worked as a Medical Resident at the Cardinal Wyszynski Institute of Cardiology in Warsaw, where he focused on innovative therapy methods in the Intensive Cardiac Care Unit. He also served as a lecturer at the Poznan University of Medical Sciences, focusing on Telemedicine.
Clinical Research Services Europe at ICON, 36 years of Clinical Development & General Management experience, covering all phases of drug development I-IV, including most Therapeutic Areas, including both major Pharma (Abbott laboratories & Schering Plough) as well as major Biotech (Amgen) and CRO experience (Kendle, INC).
Medical background with Medical Doctor license from Erasmus University Rotterdam, 1985, followed by 4 years of clinical experience in direct patient care in internal medicine and cardiology.
Agnieszka Kulesza is the Chief Operating Officer at Biokinetica, bringing over 20 years of unique experience in managing early-phase clinical research for biotech and pharma companies, including numerous Phase 1 trials with biosimilars.
She was elected as the President of the POLFEMED Association (a member of EUFEMED), an organization dedicated to promoting education in the development of innovative therapies and strengthening the clinical research sector in Poland.
